Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
09860 艾迪康控股
Listing Date2023/06/30
Listing Price12.320
  • 8.430 +0.230 (+2.805%)    Sink Below Listing Price
  • 15-min delayed, last update: 27/05/2024 17:59
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    1 lot
  • One Lot Success Rate

ADICON Holdings is one of the top three independent clinical laboratory, or ICL, service providers in China in terms of total revenues. It offers comprehensive and best-in-class testing services primarily to hospitals and health check centers through an integrated network of 33 self-operated laboratories across China.


As of December 31, 2022, 18 of laboratories were accredited by ISO1518. Its testing portfolio consists of over 4,000 medical diagnostic tests, including over 1,700 routine tests and over 2,300 esoteric tests.


The Group operates a dedicated cold-chain logistics network covering more than 19,000 customers across 30 provinces and municipalities and over 1,600 cities and counties in China by the end of 2022. It also assembled a dedicated sales and marketing team of over 1,500 personnel.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot500
No. of Offer Shares33.19M shares
No. of International Offer Shares29.87M shares
No. of HK Offer Shares3.32M shares
Offer Price$12.32
Stock Code9860
Sponsor(s)Morgan Stanley Asia Limited, Jefferies Hong Kong Limited
Underwriter(s)Morgan Stanley Asia Limited, Jefferies Hong Kong Limited, CLSA Limited, Deutsche Bank AG, Hong Kong Branch, Haitong International Securities Company Limited, The Hongkong and Shanghai Banking Corporation Limited, CCB International Capital Limited, Futu Securities International (Hong Kong) Limited, Huatai Financial Holdings (Hong Kong) Limited, ICBC International Securities Limited, Tiger Brokers (HK) Global Limited, Valuable Capital Limited
Application PeriodJun 19 (Mon) - noon, Jun 23 (Fri)
Price Determination Date--
Result Announcement DateOn or before Jun 29 (Thu)
Result Announcement DateOn or before Jun 29 (Thu)
Result Announcement DateOn or before Jun 29 (Thu)
Dealings in Shares commence onJun 30, 2023. (Fri)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$12.32
NAV / share ($)$1.54 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 12.32, the net proceeds raised would be HKD 83.90M, of which
15% : Strengthening routine and esoteric testing capabilities
25% : Network expansion through establishing new laboratories, partnership investments and development of new channels
25% : Business development activities bringing in both new technologies as well as strategic and bolt-on acquisitions;
15% : Upgrade and expansion of existing laboratories
10% : Investment in operating infrastructure
10% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.